Antonis Kattamis, EHA 2019 – Transfusion-dependent Thalassemia and the DEEP-2 Trial
We are joined by Antonis Kattamis at the EHA conference in Amsterdam to discuss his presentation on data from the DEEP-2 trial, a multicentre, randomised, non-inferiority trial comparing the efficacy of deferiprone versus deferasirox in paediatric patients affected by transfusion-dependent haemoglobinopathies.
Questions
1. What are the complications of lifelong red blood cell transfusions in transfusion-dependent thalassaemia (TDT)? (0:05)
2. How have recent therapeutic advances affected outcomes in TDT? (0:40)
3. Could you tell us a little about your recent study of TDT patients? (1:07)
4. What were the main factors affecting efficacy of iron chelation in this group of TDT patients? (1:50)
5. What can be done to further improve outcomes in this patient population? (2:38)
Antonis Kattamis has received study support, speaker fees and is a member of the advisory board for Novartis Oncology, and has received speaker fees from Apopharma.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
